Searching On:

Drug:

MEHD7945A

View:
Expand Collapse MEHD7945A  - General Description MEHD7945A is a phage-derived, human IgG1 monoclonal antibody. It was developed using a novel antibody-engineering platform to allow specific high-affinity binding to EGFR or HER3 with either antigen-binding fragment (Fab). When bound to these receptors, MEHD7945A blocks their ligands from binding, resulting in inhibition of ligand-driven signaling from EGFR/EGFR, EGFR/HER2, EGFR/HER3, and HER2/HER3 dimer pairs.

Drug Code Name
MEHD7945A
MEHD7945A is a phage-derived, human IgG1 monoclonal antibody. It was developed using a novel antibody-engineering platform to allow specific high-affinity binding to EGFR or HER3 with either antigen-binding fragment (Fab). When bound to these receptors, MEHD7945A blocks their ligands from binding, resulting in inhibition of ligand-driven signaling from EGFR/EGFR, EGFR/HER2, EGFR/HER3, and HER2/HER3 dimer pairs.

Drug Code Name
MEHD7945A

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (D) - Drug
Trial Status: No record found.
Protocol # Title Location Status Match
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
There are currently no clinical trials available for your selection. New clinical trials are being approved every day. Please continue to check back for updates.
Trial Status: No record found.

Share with your Physican

Print information for your Physician.

Print information